Regeneron Pharmaceuticals (REGN) reported positive Phase 3 results for cemdisiran in Generalized Myasthenia Gravis, with the NIMBLE trial meeting primary and key secondary endpoints at 24 weeks.
Cemdisiran-treated patients showed significant improvements in MG-ADL and QMG scores versus placebo, with placebo-adjusted gains of 2.3 points and 2.8 points, respectively.
Clinical benefits appeared within two weeks and were sustained through the study period. Notably, 76.6% of patients achieved =3-point MG-ADL improvement compared to 44.1% on placebo.
The investigational siRNA therapy targets complement factor C5 and is administered once every 12 weeks, offering a potentially more convenient treatment option.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.